2025 Q3 -tulosraportti
29 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,81 %Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
227
Myynti
Määrä
401
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 168 | - | - | ||
| 68 | - | - | ||
| 69 | - | - | ||
| 168 | - | - | ||
| 51 | - | - |
Ylin
312,85VWAP
Alin
307,8VaihtoMäärä
341 1 098 109
VWAP
Ylin
312,85Alin
307,8VaihtoMäärä
341 1 098 109
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 161 764 | 1 161 764 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 161 764 | 1 161 764 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11. | |
| 2025 Q3 -tulosraportti | 6.11. | |
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| 2025 Q2 -tulosraportti | 6.8. |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·24 min sittenEli Lilly is going down, Novo is going up.. Is it about to turn?
·32 min sittenDoes anyone know where Nordnet gets their forward P/E from? I'm looking at 2027 where it's estimated at 12.45, it's currently at 13.11. Does this mean that earnings are only expected to increase by 3% from the current estimated 2025 earnings over the next 2 years? Has Novo itself announced this?
·30 min sitten · MuokattuIt's quite wild that Novo's communication strategy simply consists of talking the stock down as much as possible: "The financial institution Berenberg writes this, after a meeting with CFO Karsten Munk Knudsen." "The CFO has reiterated to Berenberg the many headwinds that the pharmaceutical giant faces in 2026." Excuse me, but I have never experienced anything like it.·27 min sitten · MuokattuI perceive KK as an accounting nerd who doesn't have a clue how to act professionally in relation to analysts and investors. He thinks he should be as "honest" as possible, but the problem is that he doesn't even know how sales will develop in 2026. Of course, he shouldn't say anything about that either, but maybe he should just keep his mouth shut about what he believes from his nerd perspective, and then Novo should let the CEO speak. Then we might also hear something about the CEO's work to get sales going.- ·44 min sittenAll analysts' estimates are based on one key factor that is absolutely crucial for where they set their price targets, and that key factor is subjective (and adjusted to today's price, so the busy analyst doesn't stand out too much IMO). One thing is that analysts calculate and guess future sales and costs, another thing is then what value they believe it should have in relation to the P/E ratio. It is absolutely given that this key factor is very different between Novo Nordisk and Eli Lilly, for example. One can talk at length about Eli Lilly's merits, but fundamentally, the key factor is based on free imagination and the analyst's own personal opinion, not on facts, because there are no facts about what the future looks like. Analysts with low price targets will defend their key values for Lilly and Novo respectively by arguing that they do not believe Novo will grow in the next couple of years (at least not next year), and therefore the key factor must be much lower for Novo than for Lilly, but we all know how much sentiment in the stock market matters, and it only takes a small shift in sentiment for prices to move quite dramatically. I still hold my Novo shares.
·25 min sittenFundamentally, analysts' price targets mean nothing; the 'real' numbers will eventually come to light, so one doesn't need to be so nervous about whether they are right or wrong. If one reads along here, one quickly gets the impression that analysts are some of the most fact-resistant, incompetent, and manipulative people there are.
·12 min sitten · MuokattuNovo itself has enormous problems getting its guidance right. The last couple of times, the market has downgraded Novo's guidance before the company itself did. A little worrying. Analysts are actually fantastically competent, here, given what their targets are. 
·51 min sittenHave you sold at a loss for tax deduction? The rest of us want to go north.·8 min sitten · MuokattuThat sounds great with deductions! You get no deduction, you merely stand in minus with SKAT until you are again in plus and have a surplus.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
29 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,81 %Tuotto/v
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·24 min sittenEli Lilly is going down, Novo is going up.. Is it about to turn?
- ·32 min sittenDoes anyone know where Nordnet gets their forward P/E from? I'm looking at 2027 where it's estimated at 12.45, it's currently at 13.11. Does this mean that earnings are only expected to increase by 3% from the current estimated 2025 earnings over the next 2 years? Has Novo itself announced this?
- ·30 min sitten · MuokattuIt's quite wild that Novo's communication strategy simply consists of talking the stock down as much as possible: "The financial institution Berenberg writes this, after a meeting with CFO Karsten Munk Knudsen." "The CFO has reiterated to Berenberg the many headwinds that the pharmaceutical giant faces in 2026." Excuse me, but I have never experienced anything like it.·27 min sitten · MuokattuI perceive KK as an accounting nerd who doesn't have a clue how to act professionally in relation to analysts and investors. He thinks he should be as "honest" as possible, but the problem is that he doesn't even know how sales will develop in 2026. Of course, he shouldn't say anything about that either, but maybe he should just keep his mouth shut about what he believes from his nerd perspective, and then Novo should let the CEO speak. Then we might also hear something about the CEO's work to get sales going.
- ·44 min sittenAll analysts' estimates are based on one key factor that is absolutely crucial for where they set their price targets, and that key factor is subjective (and adjusted to today's price, so the busy analyst doesn't stand out too much IMO). One thing is that analysts calculate and guess future sales and costs, another thing is then what value they believe it should have in relation to the P/E ratio. It is absolutely given that this key factor is very different between Novo Nordisk and Eli Lilly, for example. One can talk at length about Eli Lilly's merits, but fundamentally, the key factor is based on free imagination and the analyst's own personal opinion, not on facts, because there are no facts about what the future looks like. Analysts with low price targets will defend their key values for Lilly and Novo respectively by arguing that they do not believe Novo will grow in the next couple of years (at least not next year), and therefore the key factor must be much lower for Novo than for Lilly, but we all know how much sentiment in the stock market matters, and it only takes a small shift in sentiment for prices to move quite dramatically. I still hold my Novo shares.·25 min sittenFundamentally, analysts' price targets mean nothing; the 'real' numbers will eventually come to light, so one doesn't need to be so nervous about whether they are right or wrong. If one reads along here, one quickly gets the impression that analysts are some of the most fact-resistant, incompetent, and manipulative people there are.·12 min sitten · MuokattuNovo itself has enormous problems getting its guidance right. The last couple of times, the market has downgraded Novo's guidance before the company itself did. A little worrying. Analysts are actually fantastically competent, here, given what their targets are.
- ·51 min sittenHave you sold at a loss for tax deduction? The rest of us want to go north.·8 min sitten · MuokattuThat sounds great with deductions! You get no deduction, you merely stand in minus with SKAT until you are again in plus and have a surplus.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
227
Myynti
Määrä
401
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 168 | - | - | ||
| 68 | - | - | ||
| 69 | - | - | ||
| 168 | - | - | ||
| 51 | - | - |
Ylin
312,85VWAP
Alin
307,8VaihtoMäärä
341 1 098 109
VWAP
Ylin
312,85Alin
307,8VaihtoMäärä
341 1 098 109
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 161 764 | 1 161 764 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 161 764 | 1 161 764 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11. | |
| 2025 Q3 -tulosraportti | 6.11. | |
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| 2025 Q2 -tulosraportti | 6.8. |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
29 päivää sitten54 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11. | |
| 2025 Q3 -tulosraportti | 6.11. | |
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| 2025 Q2 -tulosraportti | 6.8. |
Datan lähde: Quartr, FactSet
3,75 DKK/osake
Viimeisin osinko
3,81 %Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·24 min sittenEli Lilly is going down, Novo is going up.. Is it about to turn?
- ·32 min sittenDoes anyone know where Nordnet gets their forward P/E from? I'm looking at 2027 where it's estimated at 12.45, it's currently at 13.11. Does this mean that earnings are only expected to increase by 3% from the current estimated 2025 earnings over the next 2 years? Has Novo itself announced this?
- ·30 min sitten · MuokattuIt's quite wild that Novo's communication strategy simply consists of talking the stock down as much as possible: "The financial institution Berenberg writes this, after a meeting with CFO Karsten Munk Knudsen." "The CFO has reiterated to Berenberg the many headwinds that the pharmaceutical giant faces in 2026." Excuse me, but I have never experienced anything like it.·27 min sitten · MuokattuI perceive KK as an accounting nerd who doesn't have a clue how to act professionally in relation to analysts and investors. He thinks he should be as "honest" as possible, but the problem is that he doesn't even know how sales will develop in 2026. Of course, he shouldn't say anything about that either, but maybe he should just keep his mouth shut about what he believes from his nerd perspective, and then Novo should let the CEO speak. Then we might also hear something about the CEO's work to get sales going.
- ·44 min sittenAll analysts' estimates are based on one key factor that is absolutely crucial for where they set their price targets, and that key factor is subjective (and adjusted to today's price, so the busy analyst doesn't stand out too much IMO). One thing is that analysts calculate and guess future sales and costs, another thing is then what value they believe it should have in relation to the P/E ratio. It is absolutely given that this key factor is very different between Novo Nordisk and Eli Lilly, for example. One can talk at length about Eli Lilly's merits, but fundamentally, the key factor is based on free imagination and the analyst's own personal opinion, not on facts, because there are no facts about what the future looks like. Analysts with low price targets will defend their key values for Lilly and Novo respectively by arguing that they do not believe Novo will grow in the next couple of years (at least not next year), and therefore the key factor must be much lower for Novo than for Lilly, but we all know how much sentiment in the stock market matters, and it only takes a small shift in sentiment for prices to move quite dramatically. I still hold my Novo shares.·25 min sittenFundamentally, analysts' price targets mean nothing; the 'real' numbers will eventually come to light, so one doesn't need to be so nervous about whether they are right or wrong. If one reads along here, one quickly gets the impression that analysts are some of the most fact-resistant, incompetent, and manipulative people there are.·12 min sitten · MuokattuNovo itself has enormous problems getting its guidance right. The last couple of times, the market has downgraded Novo's guidance before the company itself did. A little worrying. Analysts are actually fantastically competent, here, given what their targets are.
- ·51 min sittenHave you sold at a loss for tax deduction? The rest of us want to go north.·8 min sitten · MuokattuThat sounds great with deductions! You get no deduction, you merely stand in minus with SKAT until you are again in plus and have a surplus.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
227
Myynti
Määrä
401
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 168 | - | - | ||
| 68 | - | - | ||
| 69 | - | - | ||
| 168 | - | - | ||
| 51 | - | - |
Ylin
312,85VWAP
Alin
307,8VaihtoMäärä
341 1 098 109
VWAP
Ylin
312,85Alin
307,8VaihtoMäärä
341 1 098 109
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 161 764 | 1 161 764 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 161 764 | 1 161 764 | 0 | 0 |